Patents Examined by Zachariah Lucas
-
Patent number: 9434937Abstract: Methods and systems for purifying cells and/or viruses are provided. The sample is added to a well disposed in a medium. A potential is applied across the medium to cause the contaminants to enter one or more walls of the well, and retain the cells and/or viruses in the well. The cells and/or viruses can be removed from the well, and optionally adhered or fixed to a surface, or detected. In one embodiment, the cells and/or viruses may be retained in the well by embedding in the medium. The medium including the embedded cells and/or viruses may be excised or otherwise removed and transferred to a glass slide or other solid surface.Type: GrantFiled: March 7, 2012Date of Patent: September 6, 2016Assignee: ACCELERATE DIAGNOSTICS, INC.Inventors: Steven W. Metzger, Kenneth Robert Hance
-
Patent number: 9279161Abstract: The present invention relates to the development of a monoclonal antibody which has binding activity to many high-risk types of HPV, etc. The present invention also provides a simple and high-throughput method for measuring cross-neutralizing antibody titers, which is used for assay of cross-neutralizing antibody against HPV in serum samples from subjects, etc. The method of the present invention for measuring cross-neutralizing antibody titers comprises the steps of: preparing a monoclonal antibody against a peptide having a specific amino acid sequence common to high-risk types of HPV; and assaying cross-neutralizing antibody using this monoclonal antibody.Type: GrantFiled: December 26, 2011Date of Patent: March 8, 2016Assignee: Japan Health Sciences FoundationInventors: Seiichiro Mori, Tadahito Kanda
-
Patent number: 9254315Abstract: The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures.Type: GrantFiled: February 3, 2010Date of Patent: February 9, 2016Inventors: Samuel Bogoch, Elenore S. Bogoch, Samuel Winston Bogoch, Anne Elenore Borsanyi
-
Patent number: 9248178Abstract: Immunization platforms, immunization regimes and medicaments useful for inducing an immune response in a mammal and preventing or treating a pathogenic infection in a mammal, wherein said immunization platforms and medicaments comprise a recombinant vesicular stomatitis virus (VSV) of one serotype and a rVSV of another serotype and are used in a prime-boost immunization regime. In aspects of the invention one VSV serotype is Indiana and the other VSV serotype is New Jersey.Type: GrantFiled: June 8, 2010Date of Patent: February 2, 2016Inventors: Chil-Yong Kang, Gyoung Nyoun Kim
-
Patent number: 9238679Abstract: Provided herein are nucleic acid sequences encoding hepatitis B virus (HBV) core proteins, surface antigen proteins, fragments and combinations thereof as well as genetic constructs/vectors and vaccines that express said protein sequences. These vaccines are able to induce an immune response peripherally and in the liver by recruiting both cellular and humoral agents. Also provided are methods for prophylactically and/or therapeutically immunizing individuals against HBV. The combination vaccine can also be used for particular design vaccines for particular levels of immune responses to HBV challenge.Type: GrantFiled: September 19, 2012Date of Patent: January 19, 2016Assignee: The Trustees of the University of PennslyvaniaInventors: David B Weiner, Jian Yan, Nyamekye Obeng-Adjei
-
Patent number: 9234183Abstract: Described is a parvovirus, in particular a H-IPV, that can be genetically retargeted through modification of its capsid, which is useful in cancer therapy.Type: GrantFiled: April 9, 2013Date of Patent: January 12, 2016Assignee: DEUTSCHES KREBSFORSCHUNGZENTRUMInventors: Antonio Marchini, Nazim El-Andaloussi, Jean Rommelaere, Barbara Leuchs, Xavier Allaume
-
Patent number: 9233107Abstract: The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.Type: GrantFiled: September 13, 2008Date of Patent: January 12, 2016Assignee: Biogen MA Inc.Inventors: Leonid Gorelik, Margot Brickelmaier, Alexey Lugovskoy
-
Patent number: 9234008Abstract: Described herein is the generation of optimized H3N2, H2N2 and B influenza HA polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on H3N2, H2N2 and B influenza isolates. Provided herein are optimized H3N2, H2N2 and B influenza HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure.Type: GrantFiled: February 6, 2013Date of Patent: January 12, 2016Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Ted M. Ross, Donald M. Carter, Corey J. Crevar
-
Patent number: 9206396Abstract: A method for quantifying infectious particles of a virus in a sample comprises providing a layer of host cells of the virus, contacting the layer of host cells with a preparation of the sample, and culturing the cells under conditions wherein the cells are submerged in a thin layer of liquid culture medium, and wherein the virus infects host cells and releases its progeny from said infected host cells, imposing a flow of the liquid medium, wherein the spread of the viral progeny to uninfected host cells is enhanced, culturing the cells under conditions to allow further virus infection and viral gene expression, wherein infected host cells develop an observable indication of viral gene expression, and determining the number of infected host cells, whereby the number of infectious particles of the virus in the sample is quantified. The method may be used for measuring viral growth rate or for screening for antiviral compounds. Also provided are microfluidic devices suitable for the inventive method.Type: GrantFiled: November 16, 2006Date of Patent: December 8, 2015Assignee: Wisconsin Alumni Research FoundationInventors: John Yin, Ying Shu
-
Patent number: 9200062Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.Type: GrantFiled: May 21, 2014Date of Patent: December 1, 2015Assignee: GREEN CROSS CORPORATIONInventors: Se-Ho Kim, Ki Hwan Chang, Kwang-Won Hong, Yong-Won Shin, Min-soo Kim, Hae-Won Lee, Kyung Hwan Ryoo, Dong Hyuck Seo, Jean Man Kim, Yong Nam Shin, Sunmi Koo, Jung-Ae Lim, Mijung Lee, Yeon Kyung Lee, Misun Seo
-
Patent number: 9192660Abstract: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided.Type: GrantFiled: October 26, 2012Date of Patent: November 24, 2015Assignee: The Trustees of the University of PennsylvaniaInventors: David B Weiner, Matthew P Morrow, Jian Yan
-
Patent number: 9193790Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.Type: GrantFiled: December 6, 2007Date of Patent: November 24, 2015Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: James Arthos, Diana Goode, Claudia Cicala, Anthony Fauci
-
Patent number: 9187732Abstract: The present invention relates to a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and having a heterologous sequence inserted between the splice donor site and the splice acceptor site of the NS gene segment. The virus can be used as vector for expression of various proteins like chemokines, cytokines or antigenic structures and to produce vaccines. A fusion peptide comprising part of the N-terminus of an NS1 protein and a signal sequence fused to the C-terminus of said NS1 peptide is also provided.Type: GrantFiled: October 9, 2013Date of Patent: November 17, 2015Assignee: Baxalta GmbHInventors: Markus Wolschek, Andrej Egorov, Michael Bergmann, Thomas Muster, Christian Kittel
-
Patent number: 9187730Abstract: The disclosure provides for immunogenic compositions against Equine Rhinitis Virus, particularly Equine Rhinitis A and B Virus, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.Type: GrantFiled: March 12, 2012Date of Patent: November 17, 2015Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Phillip Wayne Hayes, Kristina J. Hennessy, Laurent Viel, Andres Diaz-Mendez
-
Patent number: 9175355Abstract: The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal producedType: GrantFiled: December 10, 2009Date of Patent: November 3, 2015Assignee: Monogram Biosciences, Inc.Inventors: Douglas Richman, Mary T. Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette Whitcomb, Wei Huang
-
Patent number: 9175070Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.Type: GrantFiled: September 24, 2010Date of Patent: November 3, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of WashingtonInventors: John R. Mascola, Richard T. Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary J. Nabel, Peter D. Kwong, Tongqing Zhou, Mark Connors, William R. Schief
-
Patent number: 9168236Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?-monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.Type: GrantFiled: April 10, 2012Date of Patent: October 27, 2015Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Université Claude Bernard - Lyon 1Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
-
Patent number: 9145564Abstract: A persistently infective virus vector is produced by using a gene so modified as to encode an amino acid sequence including a valine substituted for an amino acid residue at position-1618 in the amino acid sequence for an L protein of a persistently non-infective Sendai virus. A non-transmissible, persistently infective virus vector is also produced by defecting or deleting at least one of M gene, F gene, and HN gene. These virus vectors have no cytotoxicity, can achieve the sustained gene expression over a long period of time, is safe, and is therefore useful.Type: GrantFiled: April 11, 2008Date of Patent: September 29, 2015Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Ken Nishimura, Hiroaki Segawa, Mahito Nakanishi
-
Patent number: 9139620Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), nucleic acid molecules, polypeptides and antibodies related to FmoPV and uses thereof. In certain embodiments, the FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and uses thereof. Also described is a recombinant FmoPV for the prevention and/or treatment of diseases related to FmoPV or a delivery vector. Also described herein is a diagnostic assay for FmoPV, natural or artificial variants, analogs, or derivatives thereof. Also described herein is a vaccine and a kit containing the vaccine for the prevention and treatment of FmoPV infection. Also provided is a diagnostic kit comprising nucleic acid molecules for the detection of FmoPV.Type: GrantFiled: January 22, 2013Date of Patent: September 22, 2015Assignees: THE GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, VERSITECH LIMITEDInventors: Kwok-Yung Yuen, Patrick Chiu-Yat Woo, Susanna Kar-Pui Lau
-
Patent number: 9139824Abstract: The present invention pertains to a protein having the characteristics of a serine protease having an amino acid sequence according to SEQ ID NO 2 for use as a medicament. The invention also pertains to this protein for use in a vaccine to protect an animal against an infection with a micro organism that secretes said protein, and to the corresponding antibodies directed against the protein.Type: GrantFiled: April 20, 2012Date of Patent: September 22, 2015Assignee: The University Court of the University of AberdeenInventors: Pieter van West, Christopher John Secombes, Victoria Louise Anderson, Kirsty Louise Minor